KYTX
Kyverna Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.85
−0.68%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.68
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.63
- EPS estimate
- -$0.68
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +9.2%
- Revenue beats (12Q)
- —
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.68 | -$0.63 | Beat 7.12% | — |
| May 12, 2026 | -$0.75 | -$0.66 | Beat 12.00% | — |
| Mar 26, 2026 | -$0.84 | -$0.80 | Beat 5.33% | — |
| Nov 12, 2025 | -$0.97 | -$0.85 | Beat 12.37% | — |
| Aug 12, 2025 | -$1.00 | -$0.97 | Beat 3.00% | — |
| Mar 27, 2025 | -$0.87 | -$0.88 | Miss -1.15% | — |
| Feb 8, 2024 | -$3.23 | -$27 | Miss -731.58% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026